Ethical Issues in Providing Care in Safety-Net Health Systems | NEJM
Perspective from The New England Journal of Medicine — Ethical Issues in Providing Care in Safety-Net Health Systems
Related Articles
U.S. Research Leadership at a Crossroads — The Impact of Reducing NIH Indirect-Cost Coverage | NEJM
The Trump administration’s proposed 15% cap on indirect-cost rates for National Institutes of Health grants risks upending the paradigm that underpins American leadership in medical…
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | NEJM
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering…
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed…
Death by a Thousand Cuts — The Crushing Weight of Nonclinical Demands in Primary Care | NEJM
Inadequate payment is just one of many factors that negatively affect daily practice and contribute to burnout among primary care physicians. Also problematic are growing…
U.S. Research Leadership at a Crossroads — The Impact of Reducing NIH Indirect-Cost Coverage | NEJM
The Trump administration’s proposed 15% cap on indirect-cost rates for National Institutes of Health grants risks upending the paradigm that underpins American leadership in medical…
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | NEJM
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering…
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk | NEJM
Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not…
U.S. Research Leadership at a Crossroads — The Impact of Reducing NIH Indirect-Cost Coverage | NEJM
The Trump administration’s proposed 15% cap on indirect-cost rates for National Institutes of Health grants risks upending the paradigm that underpins American leadership in medical…
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed…